| Ytd | -3.88% | |
| 1y | 37.74% |
| Open | 3.63 | Prev Close | 3.64 | Low | 3.53 | High | 3.63 | Mkt Cap | 34.79M |
| Vol | 105.99K | Avg Vol | 890.25K | EPS | -2.11 | P/E | -1.73 | Forward P/E | -1.56 |
| Beta | 0.52 | Short Ratio | 1.22 | Inst. Own | 34.25% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 3.70 | 200-d Avg | 3.67 | 1yr Est | 12.40 |
SABS News
Shares of SAB Biotherapeutics, Inc. (NASDAQ: SABS - Get Free Report) have earned a consensus rating
Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization and SA
MIAMI, July 07, 2026 (GLOBE NEWSWIRE) -- Breakthrough T1D, the leading global type 1 diabetes (T1D)
Barclays analyst Eliana Merle initiates coverage on SAB Biotherapeutics (NASDAQ:SABS) with a Over
Top Wall Street analysts changed their outlook on top names. See all rating changes on our analyst r
Data will highlight deeper mechanistic insights and long-term dosing potential of SAB-142, a fully h
SAB Biotherapeutics NASDAQ: SABS said its lead type 1 diabetes candidate, SAB-142, remains on track
Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on tr
MIAMI, May 05, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage b
All 4 T1D participants receiving SAB-142 showed C-peptide preservation with 3 of the 4 participants
SAB Biotherapeutics is a clinical-stage biotech centered on SAB-142, a disease-modifying T1D candida
MIAMI, March 19, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage
MIAMI, March 17, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage
MIAMI, March 17, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage
Results demonstrated early signals of C-peptide preservation T1D key opinion leader, Michael J. Hall
Advanced SAB -142 into registrational Phase 2b SAFEGUARD study with multiple patients dosed; enrollm
MIAMI, March 02, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage
SAB Biotherapeutics, Inc. (NASDAQ: SABS - Get Free Report) has received a consensus rating of "Moder
Viking Therapeutics (NASDAQ: VKTX - Get Free Report) and SAB Biotherapeutics (NASDAQ: SABS - Get Fre
MIAMI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage
David Zaccardelli, Pharm.D. joins Board as Chair Rita Jain, M.D.
MIAMI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage
Enrollment in the SAFEGUARD trial is ongoing at multiple centers globally Company on-track to share
Wednesday's session saw 269 companies set new 52-week lows.
Tuesday's session saw 729 companies set new 52-week lows.